Endocrine-Related Cancer

Papers
(The H4-Index of Endocrine-Related Cancer is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms73
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms55
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading49
Therapy considerations in neuroendocrine prostate cancer: what next?44
The tumor microenvironment and immune responses in prostate cancer patients42
The role of vitamin D in breast cancer risk and progression42
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?35
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas34
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns34
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy34
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer33
Thyroid cancer in the age of COVID-1932
Redifferentiation-facilitated radioiodine therapy in thyroid cancer31
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)28
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues27
Molecular alterations in Hürthle cell nodules and preoperative cancer risk27
New therapeutic opportunities for women with low-grade serous ovarian cancer26
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches25
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment24
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?24
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review24
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas23
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer23
0.048924922943115